exo-2-Acetyl-exo-5-isothiocyanatonorbornane | 155309-06-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: exo-2-Acetyl-exo-5-isothiocyanatonorbornane
• 英文别名: 1-(5-isothiocyanato-2-bicyclo[2.2.1]heptanyl)ethanone
• CAS: 155309-06-1
• 化学式: C₁₀H₁₃NOS
• 分子量: 195.28
• InChiKey: JAFDGJGPXFVHSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  61.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Prevention and Treatment of Oxidative Stress Disorders by compounds which elevate intracellular levels of glutathione or Phase II Detoxification Enzymes
  申请人：Brassica Foundation for Chemoprotection Research, Inc.

  公开号：EP2138170A2

  公开（公告）日：2009-12-30

  The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathione or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from photooxidation or oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathione or intracellular levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders.

  本发明一般涉及治疗氧化应激紊乱的领域，其方法是施用一种药学有效量的化合物，该化合物能提高动物组织中谷胱甘肽的细胞内水平或至少一种II期解毒酶的细胞内水平。本发明还涉及通过给药有效量的化合物来保护受试者免受光氧化或氧化应激紊乱的领域，该化合物能提高受试者体内谷胱甘肽的细胞内水平或至少一种II期解毒酶的细胞内水平。本发明还涉及一种用于治疗氧化应激紊乱的药物组合物。
• Zusammensetzung zur Hautaufhellung enthaltend Sulforaphan oder Sulforaphen oder deren Derivate
  申请人：Henkel AG & Co. KGaA

  公开号：EP2163238A2

  公开（公告）日：2010-03-17

  Gegenstand der vorliegenden Anmeldung sind kosmetische oder dermatologische Zusammensetzungen zur Aufhellung der Haut, die 8-Hexadecen-1,16-dicarbonsäure und mindestens eine Substanz, ausgewählt aus der Gruppe, bestehend aus Sulforaphan, Sulforaphen, Sulforaphan-Analoga und Sulforaphen-Analoga, enthalten.

  本申请涉及用于美白皮肤的化妆品或皮肤科组合物，该组合物包含 8-十六烯-1,16-二羧酸和至少一种选自由莱菔硫烷、莱菔硫烷、莱菔硫烷类似物和莱菔硫烷类似物组成的组的物质。
• Prevention and treatment of oxidative stress disorders by compounds which elevate intracellular levels of glutathione or phase II detoxification enzymes
  申请人：Brassica Foundation for Chemoprotection Research, Inc.

  公开号：EP2698153A1

  公开（公告）日：2014-02-19

  The present invention generally relates to the field of treating oxidative stress disorders, by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathione or intracellular levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathione or intracellular levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders. The oxidative stress disorders that are treated or prevented are Alzheimer's disase and aging.

  本发明一般涉及治疗氧化应激紊乱的领域，方法是施用一种药学有效量的化合物，该化合物能提高动物组织中谷胱甘肽的细胞内水平或至少一种II期解毒酶的细胞内水平。本发明还涉及通过给药有效量的化合物来保护受试者免受氧化应激紊乱的领域，该化合物能提高受试者体内谷胱甘肽的细胞内水平或至少一种II期解毒酶的细胞内水平。本发明还涉及一种用于治疗氧化应激紊乱的药物组合物。可治疗或预防的氧化应激紊乱包括阿尔茨海默氏症和衰老。
• Methods and compositions for treatment of autism
  申请人：The Johns Hopkins University

  公开号：EP2859890A2

  公开（公告）日：2015-04-15

  Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder. More particularly, said methods and compositions utilise hydroxyurea.

  本文公开了治疗自闭症的方法和组合物。 本文公开了治疗自闭症谱系障碍的方法和组合物。 更具体地说，所述方法和组合物利用羟基脲。
• CHALLENGE TEST FOR DIAGNOSING SUBTYPE OF AUTISM SPECTRUM DISEASE
  申请人：Stalicla S.A.

  公开号：EP3479845A1

  公开（公告）日：2019-05-08

  The present invention is directed to a method of identifying autism spectrum disorder (ASD) subtype 1 patients, wherein the method comprises: administering an Nrf2-activator to an ASD patient previously diagnosed with ASD or a subject displaying clinical signs of ASD, and identifying the ASD patient as an ASD subtype 1 patient if the patient shows a negative response after administration of the Nrf2-activator. Likewise, the present invention is directed to an Nrf2-activator for use in identifying autism spectrum disorder (ASD) subtype 1 patients, wherein the Nrf2-activator is administered to a subject, wherein the subject is a patient previously diagnosed with ASD or a subject displaying clinical signs of ASD and wherein an ASD subtype 1 patient is identified by a negative response.

  本发明涉及一种鉴别自闭症谱系障碍（ASD）亚型1患者的方法，其中该方法包括：向先前诊断为ASD的ASD患者或显示ASD临床症状的受试者施用Nrf2-激活剂，如果患者在施用Nrf2-激活剂后显示阴性反应，则将该ASD患者鉴别为ASD亚型1患者。同样，本发明涉及一种用于鉴定自闭症谱系障碍（ASD）亚型1患者的Nrf2-激活剂，其中将Nrf2-激活剂施用给受试者，受试者是先前诊断为ASD的患者或显示ASD临床症状的受试者，并且通过阴性反应鉴定ASD亚型1患者。